Micro-RNA Profiling as a Predictor of Clinical Outcomes for Head and Neck Cancer Patients

Author(s): Tatyana Isayeva*, Margaret Brandwein-Gensler, Maheshika Somarathna, Lakisha D. Moore-Smith, Timmy Lee

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 32 , 2017

Become EABM
Become Reviewer
Call for Editor


Head and neck cancer is one of the leading malignancies worldwide. Due to the lack of symptoms in the early stage of the disease, about two thirds of patients present with locally advanced disease at the time of diagnosis. Even with significantly improved survival rates over the past two decades due to advanced imaging and treatment modalities, locoregional recurrence rates in patients with advanced disease ranges from 16% to 35%. Alternative therapeutic targets are being developed to improve survival outcomes. MicroRNAs (miRNA or miRs) are a family of small non-coding RNA species that have been demonstrated to regulate all cellular, physiological and developmental processes. Recently, there has been an exponential increase in the number of studies suggesting that miRNA is involved in regulating tumor metastasis, chemoresistance, radioresistance and survival outcomes. MiRNA candidates have been identified as potential prognostic biomarkers to diagnose cancer stages and progression, as well as to monitor follow-up treatment. In this review, we will discuss the miRNA profile in each stage of head and neck patients' therapy, with an emphasis on its application to clinical outcome prognosis.

Keywords: Head and neck cancer, human papilloma virus, saliva, microRNA, dysregulation, resistance, prognostic marker, outcome.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 21 December, 2017
Page: [4729 - 4744]
Pages: 16
DOI: 10.2174/1381612823666170601100633
Price: $65

Article Metrics

PDF: 24
PRC: 3